Wednesday, 29 April 2020

Smart Biosensors Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Market Highlights
Smart biosensors are medical devices used for chemical and biological analysis of a human body or any biological substance. Smart biosensors are advance and more effective than other traditional sensors. The increasing prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and increasing awareness about advance biosensors are the major factors driving the growth of the global smart biosensors market. According to the International Diabetic Federation, about 415 million people across the globe were reported to have diabetes in 2015, and this number is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India respectively.
The rising cost of biosensors and unfavorable reimbursement policies may hamper market growth during the forecast period.
Regional Analysis
The Americas are likely to dominate the global smart biosensors market due to the rising prevalence of chronic disorders, favorable policies implemented by government and regulatory authorities, and the adoption of highly advanced technology. The European market is expected to be the second-largest smart biosensors market. The presence of well-established healthcare system in the region, government initiatives for controlling chronic disorders, and increase in a population suffering from cardiovascular disorders are the factors responsible for the growth of the smart biosensors market in the region. Asia-Pacific is anticipated to be the fastest-growing smart biosensors market during the forecast period owing to the increasing prevalence of diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. The market in the Middle East & Africa is likely to account for the smallest share of the global smart biosensors market.
Segmentation
The global smart biosensors market has been segmented on the basis of product type, technology, application, and end user.
On the basis of product type, the market has been classified as wearable biosensors, non-wearable biosensors.
The technology segment has been divided into electrochemical biosensors, piezoelectric biosensors, optical biosensors, thermal biosensors, nanomechanical biosensors, and others. thermal biosensors segment is likely to be the fastest growing segment during the forecast period.
Based on application, has been segmented into blood glucose testing, cholesterol testing, blood gas analysis, pregnancy testing, drug discovery, infectious disease testing, and others.
The end user segment has been divided into point-of-care, home diagnostics, research labs, security & biodefense, environmental monitoring, food & beverage industry, and others.
Key Players
Some of the key players in the global smart biosensors market are Abbott Point of Care Inc., Medtronic Inc., F. Hoffman La-Roche Ltd., Siemens Healthcare AG, Lifescan, Inc., LifeSensors Inc., Nova Biomedical Corp., Acon Laboratories Inc., Universal Biosensors, Pharmaco-Kinesis Corporation, Biacore, and others.
Posted by at No comments:

Global Pharmaceutical Analytical Testing Outsourcing Market 2020 Insights Business Opportunities, Current Trends and Restraints Forecast 2023

Market scenario
Increasing research and development investments is the key factor driving the pharmaceutical analytical testing outsourcing market. For instance, in 2018, Almac Group announced that it will invest USD 493,000 in additional nuclear magnetic resonance instrumentation at its headquarters in Craigavon, UK.
The Global Pharmaceutical Analytical Testing Outsourcing Market is slated to expand at a considerable rate and at a healthy 7.45% CAGR over the predicted years (2018-2023). Analytical testing plays a key role in the field of pharmaceutical development right from the initial stages of commercialization of the therapy or drug. It is a vital phase in drug manufacturing that includes identification, determination as well as purification of a single compound and/or mixture of compounds. This process also includes determining the chemical compounds’ structure along with helping in the characterization and synthesis of active pharmaceutical ingredients (APIs).
Various other factors such as intense competition among pharmaceutical companies, increasing awareness about product quality, and safety and changing regulations for in vivo and in vitro tests are also expected to propel the growth of the market.
However, lack of awareness, and quality approvals and regulatory audits conducted in outsourcing laboratories can hinder the market growth over the forecast period.
Key players
Some of the key players in the global Pharmaceutical Analytical Testing Outsourcing market are SGS SA, Toxikon, Inc, Eurofins Scientific, Pace Analytical Services LLC, Intertek Group plc, Pharmaceutical Product Development, LLC, Exova Group plc, Boston Analytical, Charles River Laboratories International, Inc, West Pharmaceutical Services, Merck KGaA, WuXi AppTec, Source BioScience and others.
Segmentation
The Global market for pharmaceutical analytical testing outsourcing, by product type is segmented into raw materials, finished products and active pharmaceutical ingredients.
The market, by services, is segmented into bioanalytical testing, method development & validation, stability testing, and others. The bioanalytical testing segment is further classified as clinical and non-clinical. The method development & validation segment is further classified as extractable & leachable, impurity method, technical consulting and others. The stability testing is further classified as drug substance, stability indicating method validation, accelerated stability testing, photostability testing and others.
Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations and others.
Regional Market Summary
The Americas dominated the global market for pharmaceutical analytical testing outsourcing. This can be attributed to the presence of major market players and increasing awareness about product quality, and safety within the region.
Europe stood second in 2017 owing to the increasing participation of market players and presence of developed economies like UK, Germany, France, and others within the region provides a driving force for the market to grow. In 2017, Eurofins Scientific acquired EAG Laboratories to enter into the dynamic and growing Materials and Engineering Sciences markets.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing research and development investment, increasing penetration of the market players within the region, and increasing government’s support for foreign investments drives the regional markets of the Asia Pacific region.
On the other hand, the Middle East and Africa held least share in the global pharmaceutical analytical testing outsourcing market due to the presence of poor economies and low per capita income, especially within the African region. The Middle Eastern region is estimated to be a major market for the Middle East and African region.
Posted by at No comments:

Global Mortuary Refrigerator Market 2020 Business Insights & Deep Analysis to 2023 by World’s Top 10 Key Players

Mortuary refrigerators are used to keep dead bodies as a solution to maintain hygiene requirements in hospitals. The key factors contributing for the market growth are growing number of cancer patient and cancer-related research, increasing organ transplant, and growing demands for automation in mortuary procedures. Also, the increasing geriatric population, is contributing to drive the market. According to the United Census Bureau, the global-female-geriatric population is estimated to reach 4,139 million by 2030 from 3,601 million in 2015. However, the minimal awareness about mortuary equipment and fluctuating prices of raw materials and substituting products for mortuary refrigerators hinders the market growth.
The global mortuary refrigerator market is expected to register a CAGR of 4.3% during the forecast period of 2018 to 2023.
Mortuary refrigerators are the largely used equipment in the whole mortuary equipment market. These refrigerators have available with several features such as temperature adjustable knob, multiple chambers. Mortuary refrigerators are available in both positive and negative temperature facility. The positive temperature refrigerator slows down the degradation process of dead bodies for a period of time, and the negative temperature mortuary refrigerators are used to storage the body by freezing it and prevent degradation for longer duration. The increase in technology and rising demand for automation in mortuary procedures is one of the reasons for the larger share of the market.
Segmentation
The global mortuary refrigerator market is segmented on the basis of product type, application, application, end user, and region.
On the basis of product type, the market is segmented into positive temperature, negative temperature refrigerators.
By application, the market is categorised into corpses storage and forensic investigation. On the basis of end-user, the global mortuary refrigerator market is categorised into forensic labs, research and academics, funeral homes, hospitals and clinics, and others.
Regional Market Summary
The Americas dominates the global market for mortuary refrigerator owing to the increase in cancer and cancer-related research activities, increasing number of geriatric populations with health-related problems and presence of major market players within the region boosts the market growth. According to the Administration for Community Living in 2016, the number of older women within the region was estimated to be 26.7 million. Furthermore, the presence of developed economies and regulations by various authorities in healthcare sector within the region boosts the market growth.
In 2017, it was estimated that Europe stood second in the global mortuary refrigerator market. The increase in demand for mortuary refrigerator by forensic labs and hospitals to store the dead bodies for investigation increases the market growth. These equipment’s are also, used to store the entire body donated for medical research purpose, which are used in medical colleges to teach human anatomy.
Asia Pacific was the fastest growing region for the global mortuary refrigerator market in 2017. Factors such as increasing awareness about the advanced and innovative mortuary refrigerator, growing regulations and policies by various authorities regarding the hygiene in hospital drives the market growth.
On the other hand, the Middle East and Africa holds a least share in the global mortuary refrigerator market due to the lack of awareness about the advanced mortuary procedures and mortuary refrigerator hinders the market growth in this region.
Key Players
There are several Mortuary Refrigerator Market Manufacturers involved with advanced features and ease to use. However, the cost of mortuary refrigerators compare to other mortuary related products and presence of alternative products in the market are hindering the market growth.
Some of the key players in the global mortuary refrigerators market are LEEC (UK), Hygeco (Saint-Ouen, (UK)), Paragon scare Ltd. (London), Thalheimer Kühlung (UK), Barber Medical (UK), CEABIS (Italy), EIHF Isofroid (UK), EVERmed (Italy), and Fiocchetti and Funeralia (UK) and others.
Posted by at No comments:
Labels:

Leukemia Therapeutics Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Leukemia Therapeutics Market Scenario:
The clinical condition an in which an increased number of abnormal leucocytes or generally called white blood cells of malignant characteristic is called leukemia. Frequent infections, fever with chills and fatigue are early signs of leukemia. Acute, chronic, lymphocytic, and myelogenous leukemias are classified under leukemia. Cancer statistics center of American Cancer Society estimates 61780 new cases of leukemia in 2019. Treatment for such a malicious disease requires intense therapeutic attention. Therefore, the need for accurate treatment in the rising population of leukemia patients is the major factor impelling the global leukemia therapeutics market growth. The traditional therapies involved in the treatment of leukemia are chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The complex pathology of leukemia demands advancements in medical infrastructure for treatment. Hence, letting the market key players immense opportunity to invest in research and development and bring forth innovation in the leukemia therapy. This generates a lead for clinical researchers to investigate better drug administration methods. Efforts which are being made to deliver more effective leukemia therapies is likely to trigger the leukemia therapeutics industry market growth.
However, on the flip side, the high cost of existing leukemia therapies and investment required for developing new therapies is curbing the expansion of leukemia therapeutics market share.
Global leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held the value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% during the assessment period predicts Market Research Future (MRFR).
Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.
Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Top Key Players
  • Eisai Co., Ltd (Japan)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Bristol-Myers Squibb Company (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Sanofi S.A. (France)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Amgen Inc (US)
  • Takeda Pharmaceutical Company Ltd (Japan)
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.
Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.
The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the leukemia therapeutics market.
Posted by at No comments:

Global Plasma Fractionation Market 2020 Size, Trends, Industry Analysis, Leading Players & Future Forecast by 2023

Plasma Fractionation Market Scenario:
Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
Rising participation of market players is one of the key factors driving the plasma fractionation market. For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million. With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.
In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.
Global Plasma Fractionation Market Growth expected to rise significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.
Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.
However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.
Segmentation
The global plasma fractionation market is segmented based on product, application, end user, and region.
The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.
Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.
Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.
On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.
Posted by at No comments:

Global Atherectomy Devices Market 2020 – Investment Strategy, Outlook and Key Development till 2023


Market Scenario
Atherectomy devices are built to either shave, cut, vaporize, laser or sand the plaques. The devices come with different indications. Different atherectomy devices have been invented for commercial use. The location of the plaque and type of blockage influence the choice of atherectomy device to be used. Some atherectomy devices are used only in the larger arteries on the upper portion of the knee, while other devices come with smaller catheters that are suitable for operating the arteries below the knee.
Atherectomy is a technique applied to eliminate atherosclerotic plaque from affected arteries. The plaques are in either peripheral or coronary arterial vasculature and may have distinct characteristics depending on the nature of the plaque. Atherectomy is used widely in cure of both peripheral and coronary arterial ailments. It is a minimally invasive endovascular surgery.
The worldwide Atherectomy devices industry is likely to develop remarkably over the forecast period. It is projected that the global atherectomy devices market will register a CAGR of 6.12% over the forecast period of 2018–2023. In 2017, the estimated market value was around 1.09 billion.
The growing rate of peripheral and coronary arterial diseases coupled with increasing demand for minimally invasive techniques is predicted to boost the growth of the atherectomy devices market. Minimally invasive surgical techniques deliver quicker recovery, quick procedural time, lesser risk of infections and complications. The worldwide atherectomy devices market is likely to witness noteable surge in demand due to exponential growth in the incidence of lifestyle-related ailments and elderly population.
Segmentation
The global atherectomy devices market is segmented on the basis of product type, application, and end user.
Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.
The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.
On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific was projected to be the fastest growing region for the global atherectomy devices market. This owes to the technological advancements resulting in the development of cost-effective atherectomy devices leading to high acceptance rate for the devices in the Asia-Pacific region. The Middle East and Africa holds the least share in the global atherectomy devices market due to the presence of economically diverse countries, and less initiatives taken by the government.
It is projected that the Americas dominated the global atherectomy devices market owing to the growth of the market in the North American region. This is largely attributed to the factors such as increase in research funding, and growing awareness about the high-end atherectomy devices among medical professionals. Europe is expected to hold the second largest share in the atherectomy devices market owing to growing healthcare infrastructure. Additionally, various initiatives by public and private organizations is anticipated to boost the growth of the atherectomy devices market.
Browse More Report Details @ https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322

Posted by at No comments:

Global Dental Bone Graft Substitutes Market 2020 Size, Trends, Industry Analysis, Leading Players & Future Forecast by 2023

Market Highlights
The global dental bone graft substitutes anticipated to have held a market value of USD 461.3 million in the year 2017 and is expected to grow at a CAGR of 9.4% during the forecast period.
The increasing incidence of oral diseases such as, dental caries and periodontal diseases, growing ageing population, and growing medical tourism in developing countries are expected to drive the growth of market. Dental tourism is increasing because dental patients mostly from a developed country are getting attracted towards other developing countries. Dental patients prefer to travel to the countries because these countries are providing cost effective and high-quality treatment. Mostly, the treatments in the dental tourism centers around the demand for dental implants. Countries like Hungary, India, South Korea and Turkey are increasingly gaining popularity in the area of dental tourism for their low cost and effective oral health treatment. On other hand, lack of proper reimbursement and stringent regulations can restrain the market growth over the assessment period. Moreover, increasing burden of oral diseases drive the growth of the market. According to Centers for Disease Control and Prevention (CDC), about 64.7 million Americans were suffered with periodontal disease.
Regional Analysis
Geographically, the Europe is expected to dominate the global dental bone graft substitutes market owing to the presence of well-established players, increasing incidence of oral diseases namely, dental caries and periodontal diseases, and growing ageing population. The Americas is expected to hold the second largest position in the global dental bone graft substitutes market. Asia-Pacific is expected to be the fastest growing market owing to growing medical tourism in developing countries and growing ageing population. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global dental bone graft substitutes market.
Segmentation
The global dental bone graft substitutes market has been segmented into type, application, and end user.
Based on type, dental bone graft substitutes market is segmented into allograft, xenograft, alloplast, and others.
Based on application, dental bone graft substitutes market is segmented into ridge augmentation, sinus lift, socket preservation, periodontal defect, and implant bone regeneration.
Based on end user, dental bone graft substitutes market is segmented into dental clinics, hospitals, and others. The dental clinics segment is expected to account for the largest share segment of the global market in 2017.
Key Players
Some of the prominent players operating in the global dental bone graft substitutes market are Biohorizons Iph, Inc. (US), Geistlich Pharma AG (Switzerland), Dentsply Sirona (US), Institut Straumann AG (Switzerland), Medtronic Plc (Ireland), Zimmer Biomet Dental (US), Dentium (South Korea), LifeNet Health (US), and Orthogen, LLC (US).
Posted by at No comments:

MEA Anti-Fungal Agents Market 2020 Size, Trends, Industry Analysis, Leading Players & Future Forecast by 2022

Market Highlights
Anti-fungal agents are used in the treatment of infections caused by fungus. According to global action fund for fungal infection, globally, over 300 million people of all ages suffer from a serious fungal infection every year. The market drivers include rising prevalence of fungal infections, rising awareness, rise of immunity deficient population such as geriatrics, rise in exposure to infectious agents due to environmental factors such as pollution especially by particulates and agriculture residues and climatic conditions such as humidity and temperature, occupational hazards such as Jock itch, crowding etc. Growth of fungal infection due to off label use of broad spectrum antibiotics is a prime factor for the growing market for anti-fungal agents.
The market restraints include rising resistance to anti-fungal agents, use of air filters and air conditioning, excellent spectrum and efficacy of Azole class of anti-fungal agents, loss of patents and genericitization etc. Competition by generics is exceptionally strong and generics account for roughly 50% of total sales for anti-fungal agents. The market penetration is very easy as there has been loss of patents of block buster drugs. Over the counter drugs are an important reasons for the growth of anti-fungal agents market.
The Middle East and Africa anti-fungal agents market is segmented into therapeutic indication which is further segmented into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class the sub-segments are azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. By route of administration the market is further divided into oral, local and others.
The market for Middle East and Africa anti-fungal agents is extremely fragmented with a number of small and big players. The market is also affected by substandard and counterfeit products especially in poorer regions of Africa with weak regulatory framework. Product development especially for resistant fungal infections has the highest potential among all the strategies.
Key Players:
The major participants of this market are: Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others
Middle East and Africa Anti-Fungal Agents Market:
The Middle East and Africa Anti-fungal agents market has been evaluated as a growing market and it is expected that the market will grow at a moderate CAGR in future. The Middle East and Africa Anti-fungal agents market is expected to grow with CAGR of ~3.5% during the forecast period. The growth will be primary channeled by the need of unmet medical needs, rising incomes of the population and the high prevalence of fungal infection in Africa. Environmental factors such as high humidity and temperature along with the rich biodiversity of Africa will positively affect the market growth of anti-fungal agents.
Regional Analysis:
Depending on geographic region, anti-fungal agents market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. However the future market will be led by the poor developed parts of Africa due to large unmet needs and the seasonal climatic conditions of Africa. The eastern parts of Africa is expected to have greater market share as compared to the hot and dry western coast.
Segmentation:
Middle East and Africa anti-fungal agents market has been segmented on the basis of therapeutic indication which comprises into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class; market is segmented into azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of administration; market is segmented into oral, local and others.
Posted by at No comments:

Global Hepatitis C Drugs Market 2020 Industry Analysis, Share, Growth, Trends and Forecast 2022

Overview: 
Market Research Future (MRFR) has released a new report on the global hepatitis C drugs market. The report provides a complete overview of the market’s historical statistics and growth trajectory, in addition to elaborating on the market’s present statistics and providing detailed projections regarding the market’s likely growth trajectory over the forecast period from 2016 to 2022. The global hepatitis C drugs market is expected to exhibit a steady 3.3% CAGR over the forecast period, rising from a valuation of USD 18.7 billion in 2015 to USD 22.7 billion by 2022.
The slow CAGR of the global hepatitis C drugs market is due to the steady drop in the number of patients of hepatitis C in developed regions and the increasing prospects of the unorganized herbal medicine industry in emerging regions.
Thanks to consistent healthcare advancement initiatives and awareness efforts, the prevalence of hepatitis C has fallen in developed countries over the years and could in fact dip into negatives over the coming years due to the widespread availability of medication and widespread awareness about the disease. The improving sanitation levels in developed countries have been vital for the drop in the prevalence of hepatitis C, as it has reduced the likelihood of the respective pathogens breeding in large amounts. The increasing awareness about hygiene and disease prevention in countries such as the U.S., Canada, the UK, France, and Germany is likely to further reduce the prevalence of hepatitis C over the coming years, restraining the growth of the hepatitis C drugs market in developed economies.
In emerging regions such as Asia Pacific, hepatitis C is considerably prevalent. However, the disease is often treated with herbal remedies, which are available more easily and much cheaper than conventional medicine. This is likely to be a major restraint for the hepatitis C drugs market over the forecast period.
Segmentation:
The global hepatitis C drugs market is segmented on the basis of drug class, medicine system, route of administration, end user, and region.
The global hepatitis C drugs market is segmented on the basis of drug class into anti-viral drugs, immuno-modulators, and others.
On the basis of medicine system, the global hepatitis C drugs market is segmented into allopathic medicine, alternative medicine, and others.
On the basis of route of administration, the hepatitis C drugs market is segmented into oral, injectable, and others. Oral administration held the dominant share in the global hepatitis C drugs market in 2015 and is likely to remain the leading revenue generator over the forecast period.
On the basis of end user, the market is segmented into hospitals and private.

Regional Analysis:
The global hepatitis C drugs market is segmented by region into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is likely to retain the dominant share in the global hepatitis C drugs market over the forecast period, followed by Europe, due to the widespread availability of advanced medication in the region. Due to the drop in the prevalence of the disease, the hepatitis C drugs market in North America and Europe is likely to remain stable or even reduce in size over the forecast period.
The hepatitis C drugs market is likely to exhibit promising growth prospects in emerging regions such as China and India over the forecast period. The growing prevalence of the disease in these regions, allied to the growing awareness about the prevention and treatment of the disease, is likely to drive the hepatitis C drugs market over the forecast period. Growth of the healthcare sector in countries such as India, China, Japan, Korea, Indonesia, Malaysia, and Singapore is likely to be vital for the global hepatitis C drugs market over the forecast period.
Competitive Analysis:
Leading players in the global hepatitis C drugs market include Gilead Sciences Inc., Johnson & Johnson, GSK, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., and AbbVie Inc.
Industry Updates:
In February 2019, Indiana’s federal court enabled Medicaid recipients to receive direct-acting antiviral medications sooner.
Posted by at No comments:

Microspheres Market 2020 Covers Global Industry Share, Size, Gross Margin, Future Trends, Demand, Business Insight by Leading Key Players Forecast till 2022

Microspheres are characteristically free flowing powders having a particle size less than 200 µm. The microspheres used are usually polymers that are classified into two material type the first one is the natural polymers and the other one is the synthetic polymers. These microspheres are used in various industries such as pharmaceutical industry, construction industry, cosmetics industry, oil & gas industry and automotive industry.
The global Microspheres market is growing with the prompt pace. The market is forecast to establish a significant growth by 2022, beyond its previous growth records in terms of value with a striking CAGR of 11.9% during the anticipated period (2017 – 2022). The global microspheres market is growing at a rapid pace. The growth of the market is majorly upsurged by various applications and advancements of microspheres in a controlled delivery system. The various application such as carriers for drugs, absorption, and desorption of substances, pulmonary drug delivery, and tissue regeneration are influencing the growth of microspheres in the field of pharmaceutical industry. Furthermore, development in new drugs, government funding in research and development of microspheres and various others applications of microspheres in the field of construction industry, cosmetics industry, oil & gas industry and automotive industry are further enhancing the market for microspheres. As there is a wide range of factors that are driving the growth of the market, there are few barriers as well that hamper the market for microspheres. One of the factors that hamper the growth of the market are fluctuating price of raw materials, huge investment in R&D and the limitation of microspheres such as, the release rate of dose may vary from one dose to another.
Global Microspheres market - Competitive Analysis
The market for microspheres is characterized by the presence of several well-established and small players, the global market for microspheres appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. To attract the customers the companies have launched the products of different materials and in different sizes. Some companies have adopted the strategy of acquisition and collaboration to expand their market and minimize the competition. Innovation is the best way to gain the market, thus, a number of companies are involved in the development of new and better products.
For instance, in January 2017, Telko has established a new partnership with Potters to supply performance solid and hollow microspheres for a variety of applications. This partnership can help both Potters and Sovitec to deal a more widespread, cost-effective and high-quality portfolio of products and services to the customers worldwide.
3M (Unites States), Potters Industries LLC (United States), AkzoNobel N.V. (Netherlands), Momentive Performance Materials Inc. (United States), Chase Corporation (United States), Matsumoto Yushi Seiyaku Company (Japan), Sigmund Lindner GmbH (Germany), Mo-Sci Corporation (United States), Trelleborg AB (Sweden), Luminex Corporation (United States) and others are some of the prominent players at the forefront of competition in the global Microspheres market and are profiled in MRFR Analysis.
Global Microspheres market   - Regional Analysis
Globally, North America holds the largest share of more than 44% of global microspheres market and is expected to be the leading market during 2016-2022. This large share is majorly attributed due to growing technology advancement in the field of medical science in the region, rapidly growing pharmaceutical industry, increasing need for the new formulations for the development of new drugs, some of the key factors driving the growth of this market.
Globally Europe holds the second largest share of about 31% of the global microspheres market.  The European market is expected to reach USD 2.44 billion by the end of the forecasted period from 2016 to 2022. Asia-Pacific region is anticipated to observe the highest growth rate in the near future due to growing healthcare and life-sciences industry, increased adoption of microspheres in developing countries, are the key drivers that are influencing the market to grow at a rapid pace in this region. Furthermore, major players are grabbing the opportunity by expanding their operating sites in the region and thus increasing the growth of this market for the forecasted period from 2016 to 2022.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microspheres-market-2268 
Posted by at No comments:

Global Osteoporosis Drugs Market Drivers, Segmentations, Key Players, Analysis & Forecast 2020 - 2022

Market Scenario:
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.
The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.
The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.
Taking all the factors into consideration, we expect the global osteoporosis industry which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.

Study Objectives Global Osteoporosis Drugs Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Key Players for Global Osteoporosis Drugs Market:
Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.

Segments:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.

Intended Audience:
  • Osteoporosis Drugs Manufacturers
  • Osteoporosis Drugs Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations
Regional Analysis of Global Osteoporosis Drugs Market:
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Posted by at No comments:

Anti-Viral Drugs Market Global Analysis, Size, Share, Trends, And Forecast 2020 to 2022

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Key Players
MRFR have enlisted some of the prominent Anti-viral drugs Market Companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 
Posted by at No comments:

Malaria Diagnostics Market 2020 Global Growth Insights, Trends, Size, Share and Forecast to 2023

The Global Malaria Diagnostics Market Expected to Garner a CAGR of 4.63% During the assessment period between 2018 and 2023. It is reported in a study released by Market Research Future (MRFR), that the market is positively influenced by a number of factors.
Malaria is a serious life-threatening disease caused by a parasite, transmitted by the bite of infected anopheles mosquitoes. Infected mosquitoes transport the Plasmodium parasite. When the infected mosquito bites you, the parasite is released into your bloodstream. Once the human body becomes the host for the parasite it travels to the liver and matures. After some days, the mature parasite enters the bloodstream and starts to infect red blood cells (RBC). Humans suffering from malaria frequently experience fever, headache, weakness, vomiting
A major factor influencing this growth is the increasing advancements in technology related to diagnostic tools and the proliferating demand for such treatments in malaria-endemic countries. Other factors driving the market growth are rising support from the government in terms of investment funds and an increase in the collaboration between the research centers and the industry. Malaria diagnostic tests play a significant role in identifying malarial cases, which thereby boosts the growth of the overall malaria diagnostic market trends and size.
However, the lack of precise monitoring standards at developing nations, acts as a major factor constraining the market. The lack of awareness among emerging nations and work regulatory framework is of particular concern for both manufacturers and healthcare providers.
Key Players
Some of the key players in the global malaria diagnostics market are Access Bio. Inc., Abbott Laboratories, Premier Medical Corporation Pvt. Ltd, Sysmex Partec GmbH, bioMérieux, Beckman Coulter Inc., Siemens Healthineers, Leica Microsystems GmbH, Nikon Corporation, Olympus Corporation, and Bio-Rad Laboratories Inc.
Segmentation
The global malaria diagnostics market has been segmented on the basis of technology and end-user.
On the basis of technology, the market has been classified as rapid diagnostic tests, microscopy, and molecular diagnostic tests. The molecular diagnostics tests are segmented into polymerase chain reaction (PCR) and real-time polymerase chain reaction (RT-PCR).
On the basis of end-users, the market has been classified as hospitals, clinics, community healthcare, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European malaria diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The malaria diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The malaria diagnostics market in the Middle East and Africa has been segmented into the Middle East and Africa. 
Regional Market Summary
In the malaria diagnostics market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. In 2016, global governments of malaria-endemic countries have invested USD 2.7 billion in malaria control and elimination efforts. The US was the largest contributor by providing USD 1 billion for the eradication of malaria.
The European market is expected to hold the least share due to the growing number of malaria-free countries in the region.
The market in the Middle East and Africa is expected to account for the smallest share of the global malaria diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. Sub-Saharan Africa remains to bring an excessively high share of the global malaria burden on the Middle Eastern and African market. the region was home to 90% of malaria incidences and 92% of malaria deaths in 2015
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism. The Asia-Pacific remains to be the second largest burden of malaria globally with 22 malaria-endemic countries accounting for roughly 28 million cases and 45,000 deaths every year. The WHO figures say that in the Asia-Pacific region, Myanmar, Pakistan, India, and Indonesia carry the highest malaria burden accounting for 89% of all malaria cases in the region.
Posted by at No comments:

Global Duodenal Cancer Market 2020 – Investment Strategy, Outlook and Key Development till 2023

Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine. The global duodenal cancer market is expected to grow slowly over the forecast period. It is estimated that the global duodenal cancer market is expected to register a CAGR ~ 3.2% during the forecast period of 2018–2023.
Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the global duodenal cancer market.
Regional Summary
Geographically, the Americas is anticipated to dominate the global duodenal cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% of people diagnosed with duodenal cancer survive it for five years. Europe is expected to hold the second largest position in the global duodenal cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for the healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East & Africa has the least Duodenal Cancer Market Share. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Segmentation
The global duodenal cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.
The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.
The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

Global Bone Biopsy Market 2020 – Investment Strategy, Outlook and Key Development till 2025

Market Scenario
Bone Biopsy market growth is driven by increasing prevalence of chronic diseases such as Chronic Kidney Disease (CKD) and demand new diagnostic services. Additionally, increasing research and development activities, technological advancements to identify the causes and risk factors associated with osteopenia and osteoporosis also fuel the market growth of global market.
The Global Bone Biopsy System Market is expected to grow at a CAGR of 5.7% during the forecast period.
According to the World Health Organisation (WHO), cancer was the leading cause of the total number of deaths globally as of 2015 and was responsible for 8.8 million deaths. The most common causal agents identified are cigarettes, cigars, pipes and chewing tobacco. According to the Cancer Research U.K, looking at the lifestyle factors responsible, it has been found that out of 3 diagnosed cases, 1 may be linked to smoking.
Bone biopsy is performed to diagnose various bone disorders such as bone cancer, bone infection, osteoporosis and chronic kidney disease. Nowadays, biopsy procedure has received great importance in oncology as one of the promising methods in cancer diagnostics. The demand for needle biopsy is found to be increasing from last few years.
Key Players in the Global Bone Biopsy Market     
  • C R Bard (U.S.),
  • Becton,
  • Dickinson and Company (U.S.),
  • Braun Melsungen AG,
  • Hologic, Inc. (U.S.),
  • Cook Medical (U.S.),
  • Devicor Medical Products Inc. (U.S.),
  • Argon Medical Inc. (U.S.)
Segmentation      
The global bone biopsy market is segmented on the basis of type, indication and end user.
On the basis of the component, market is segmented into needle biopsy and open biopsy.
On the basis of the application, the market is segmented into bone cancer, bone infection, chronic kidney disease, osteoporosis, and others
On the basis of the end user, the market is segmented into hospital & clinics, surgical centers, diagnostic centers, and others.
Regional Analysis
America holds the first position in the bone biopsy market owing to the rising prevalence of cancer in the U.S. and increasing demand for new cancer diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in healthcare diagnostic industry. The prevalence of osteoporosis is found to be higher in the population over 35 years for age. Changing lifestyle, emphasis on fitness and exercise, and overall development of medical device industry also accelerate the growth of the market.
Europe is the second largest market for bone biopsy. In Europe, there is an increasing demand for advanced bone biopsy devices, and extensive research and development activities by clinical research and academic institutes for cancer diagnosis and treatment. Germany is the largest market followed by France. The market in Germany is driven by increasing demand for specialty care services.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as kidney disease, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand of technologically advanced medical devices in diagnostic centers and availability of highly qualified medical professional dedicated to research in oncology. Additionally, rising healthcare expenditure and extensive growth of medical device industry also influence the use of medical devices for diagnosis of various diseases such as osteoporosis, diabetes, cancer, and others.
The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about cancer treatment. In the Middle East & Africa, United Arab Emirates captures the largest market share for bone biopsy owing to the availability of better healthcare infrastructure and a wide scope for research. In Africa, the market also shows a positive growth owing to development of healthcare system in African countries, and increasing demand for primary care services.

Posted by at No comments:
Subscribe to: Posts (Atom)